Evaluation of cholera vaccine candidates vcusm2 (0139), vcusm4 (el tor) and its bivalent vaccine formulation

Loading...
Thumbnail Image
Date
2008
Authors
Sinniah, Kurunathan
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Cholera has been implicated in many parts of the worlds and two serogroup identified for causing epidemic cholera are the V cho/erae 01 and V cholerae 0139. Sharp increase of cholera cases and deaths in 2006 showed potential of V cholerae to cause more sever~ damages and must not taken lightly. Better understanding of V cholerae as non-invasive organism and oral route vaccination can optimally induce intestinal immune response has led to the preference of oral cholera vaccine over parenteral cholera vaccine. Vast majority of vaccine created were directed against 01 serogro4p only. Since cross protection cannot be established between 01 and 0139 serogroup there is need for bivalent vaccine for cholera. In this study we attempted to formulate a bivalent vaccine capable of protecting against V cholerae 01 and V cholerae 0139. A bivalent vaccine composed of auxotrophic VCUSM2 and VCUSM4 previously developed was evaluated for immunogenicity, reactogenicity, safety and protective ability as well as their characteristic similarities to their respective parent strain. VCUSM2 and VCUSM4 were created by hemA mutation making them dependent on amino levulinic acid (ALA) for survival. When supplemented with optimal ALA VCUSM vaccine strains characteristically similar to parent strains but not in absence of ALA. In the absence of ALA, VCUSM vaccine strains showed weakened characteristics. Auxotrophic strains development focused on retaining characteristic features of wild types but attenuated in term of survival abilities. VCUSM2 and VCUSM4 had limited survival capabilities in various environmental waters. VCUSM2 and VCUSM4 did not cause diarrhea when xvn tested in rabbit models when compared with virulent wild type V. cholerae. Bivalent vaccine elicited immune response against both serogroups. Protection studies using high dose of virulent of either wild types showed complete protection in rabbits vaccinated with bivalent vaccine. Bivalent vaccine showed promising result in term of safety, immunogenicity, side effects and protective capabilities and can be used against both 01 and 0139 serogroups of V. cholerae.
Description
Keywords
Cholera vaccine , Vaccine formulation
Citation